Stocktoria
Krystal Biotech, Inc. KRYS
Krystal Biotech, Inc. (KRYS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $389.1M at a 52.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Citigroup | Buy (main) |
| 2026-07-14 | B of A Securities | Buy (main) |
| 2026-06-18 | TD Cowen | Buy (main) |
| 2026-06-16 | HC Wainwright & Co. | Buy (main) |
| 2026-06-01 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-22 | HC Wainwright & Co. | Buy (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.691 |
| Retained earnings / assets | 0.018 |
| EBIT / assets | 0.121 |
| Equity / liabilities | 10.676 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
| IMCR | Immunocore Holdings plc | 3/9 | 2.37 | — | +29% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2/9 | -7.27 | — | +60.6% |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
FAQ
Is KRYS financially healthy?
Krystal Biotech, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does KRYS pay a dividend?
No, Krystal Biotech, Inc. does not currently pay a dividend.
How profitable is KRYS?
In FY2025, Krystal Biotech, Inc. had a net margin of 52.6% and a return on equity of 16.8%.
What is KRYS's P/E ratio?
Krystal Biotech, Inc.'s trailing price-to-earnings (P/E) ratio is about 53.6×, based on its latest annual earnings.
What is the analyst price target for KRYS?
The average Wall-Street price target for Krystal Biotech, Inc. is $382.86, about 15.0% above the recent price, from 7 analysts (consensus: strong buy).
Is KRYS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Krystal Biotech, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 53.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.